Last reviewed · How we verify

Benzathine Penicilllin G

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Phase 3 active Small molecule

Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing peptidoglycan cross-linking.

Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing peptidoglycan cross-linking. Used for Syphilis (primary, secondary, and latent), Rheumatic fever prophylaxis, Group A Streptococcal infections.

At a glance

Generic nameBenzathine Penicilllin G
SponsorFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Drug classBeta-lactam antibiotic (penicillin)
TargetPenicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Benzathine penicillin G is a long-acting formulation of penicillin that penetrates bacterial cell walls and irreversibly inhibits transpeptidase enzymes responsible for cross-linking peptidoglycan strands. This disruption of cell wall integrity leads to bacterial cell lysis and death. The benzathine salt provides sustained release, allowing for prolonged therapeutic levels and less frequent dosing compared to aqueous penicillin formulations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: